Posted On: 01/23/2016 1:17:08 PM
Post# of 26
February 8-9, 2016 The Waldorf Astoria New York
The 18th Annual BIO CEO & Investor Conference
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).
30 minutes
Brian Culley
https://ceo16.eventsbio.com/connect/search.ww...;i(11025)=
The 18th Annual BIO CEO & Investor Conference
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).
30 minutes
Brian Culley
https://ceo16.eventsbio.com/connect/search.ww...;i(11025)=
(0)
(0)
